AI generated image (Photo by Ajou Pharmaceutical)

AI generated image (Photo by Ajou Pharmaceutical)

View original image

Ajou Pharm Co., Ltd. is moving to adopt the Korea International Financial Reporting Standards (K-IFRS) in order to enhance the reliability and transparency of its financial information and to establish a management system that aligns with global standards, thereby aiming to increase its corporate value.


Ajou Pharm recently announced that its board of directors has approved the adoption of K-IFRS and that the company will begin a full-scale transition to a financial reporting system that complies with international standards.


K-IFRS, in contrast to the rule-based Korean Generally Accepted Accounting Principles (K-GAAP), is a principle-based accounting standard that relies on fair value assessments. It is a financial information system preferred by global investors.


This adoption of K-IFRS is seen not merely as a change in accounting standards, but as a strategic decision to enhance trust with external stakeholders and to strengthen the company's foundation for mid- to long-term growth. In particular, since K-IFRS is a financial standard that is essential for future initial public offerings (IPOs), this move is regarded as a proactive measure.


Within the pharmaceutical and biotech industry, as investment in research and development increases and business diversification accelerates, the transparency of financial information and its comparability on an international level have become key elements of corporate competitiveness. Companies seeking to attract investment, form strategic partnerships, or expand into overseas markets are increasingly working to build accounting systems that are easily understood by global investors and institutions.


Ajou Pharm has established a phased transition roadmap and plans to collaborate with external experts to comprehensively refine its financial statement preparation system, accounting policies, and internal processes. Through these efforts, the company intends to ensure international comparability of its financial information and to build a more transparent and reliable management foundation.


The company stated that changes to its profit and loss structure due to the adoption of K-IFRS are expected to be limited, maintaining continuity with existing business performance while further improving the quality of its financial information.


An Ajou Pharm official commented, "This adoption of K-IFRS marks an important turning point in building a management system in line with global standards. We will strengthen communication with investors and stakeholders by providing transparent and trustworthy financial information, which will ultimately enhance our corporate value."



Meanwhile, K-IFRS is regarded as a key infrastructure for financial reporting that meets global standards, enhancing corporate financial transparency and credibility, and strengthening the foundation for communication with external stakeholders.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing